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ABSTRACT
THE POTENTIAL ROLE OF AIRAP/AIRAPL IN AMELIORATING THE TOXICITY
RELATED TO AMYLOID-BETA (Aβ) IN MAMMALIAN NEURONAL CELLS

by
Advaita Chakraborty

The University of Wisconsin-Milwaukee, 2017
Under the Supervision of Professor Wail Hassan

Alzheimer’s disease is an irreversible and progressive brain disorder that affects memory and
thinking skills. It is considered to be one of the most important causes of dementia in older
adults. The disease is accompanied by accumulation of amyloid beta (Aβ) plaques in the brains
of patients and presence of neurofibrillary tangles (NFTs) in the nerve tissue. The tangles are
formed by a protein known as protein-tau (p-tau). Aβ plaques are responsible for
neurodegeneration, cognitive decline, and loss of memory in patients affected with Alzheimer’s
disease. It is estimated that Alzheimer’s disease ranks third, just behind heart disease and cancer,
as a cause of death for the elderly in the United States. AIRAP and AIRAPL are ubiquitinbinding proteins that are thought to enhance the function of the proteasome by clearing out the
misfolded proteins from the brain. Previous studies have shown that AIP-1 (a homologue of
AIRAP and AIRAPL) was overexpressed in a Caenorhabditis elegans disease model which in
turn helped to reduce the accumulation of Aβ and thus had a protective effect against Aβ
toxicity. The purpose of our study is to test whether AIRAP and AIRAPL are protective against
the toxicity associated with Aβ in mammalian neuronal cells. We are hypothesizing that AIRAP
ii

and AIRAPL are protective against Aβ toxicity in HT22 hippocampal cells, which would
significantly decelerate the progression of Alzheimer’s disease. We have manipulated the
expression of AIRAP and AIRAPL and studied the effect of overexpression and knockdown on
Aβ toxicity. Overexpression was achieved by establishing transfected cell lines overexpressing
AIRAP and AIRAPL with help of a CMV constitutive promoter. On the other hand, knockdown
of genes was attained using specific DsiRNA. Using Trypan Blue staining, we found that cell
lines overexpressing AIRAP/AIRAPL could lower Aβ toxicity, thus increasing the number of
viable cells. Additionally, knocking down AIRAP/AIRAPL expression appeared to worsen the
condition of cells, as the number of dead cells increased, in response to Aβ treatment. With help
of real-time PCR, mRNA levels of AIRAP and AIRAPL was measured. It was shown that
expression of both AIRAP and AIRAPL was enhanced during the initial stages of induction in
cell line having induced Aβ. However, as the induction time increased, the expression levels
started to fall off. Further studies are essential to know the exact mechanism behind
AIRAP/AIRAPL protection against Aβ toxicity.
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INTRODUCTION
Alzheimer’s Disease: Global impact, symptoms, and causes
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly (1). The disease
affects around 75% of the 35 million people suffering from dementia worldwide. It is estimated
that by the year 2050, around 115 million people will be affected by AD, since the number is
increasing at a fast pace every year (2). In developing Countries, it has been reported that 1 out
of each 10 individuals who are 65 years of age or older and one-third of those who are over 85
years old, suffer from some form of dementia (2). Mild cognitive impairment (MCI) is a term
that includes a broad spectrum of cognitive impairment syndromes that precedes AD and
dementia (3). It often depicts a transitional phase between normal aging and dementia (4). The
disease leads to cognitive defects that affects memory, judgment, insight, and language functions
(5). In aging, cognitive decline is a common feature and it is observed that changes in cognition
represents early signs of neurodegenerative disease, ultimately leading to dementia (4).
Furthermore, weight loss is common in Alzheimer’s patients and this could be a marker of
approaching AD in people with MCI (3). A clinical and community-based study showed that
around 40% patients with AD have sleep disturbances (6).
AD, similar to all kinds of dementia, is caused by death of brain cells. With time, the total brain
size shrinks since the tissue has fewer nerve cells and connections (7). Postmortem/autopsy
reports showed that tiny inclusions known as plaques and neurofibrillary tangles (NFTs) are
present in the nerve tissue. Plaques are found between the dying cells in the brain. These plaques
are formed from a protein called beta-amyloid (Aβ) (7). The tangles are found intracellularly in
the brain neurons either from hyperphosphorylation of protein tau (p-tau) or disintegration of ptau, which is a tubulin-associated protein (7). The deposition of Aβ leads to the initial
1

neurodegenerative and neurotoxic cascade and relates strongly with decreased cognitive
performance in an individual (1). The main underlying causes of neurodegeneration, cognitive
decline, and memory loss are the presence of Aβ and tau-related neuropathies in the brains of
patients. Aβ peptides are 39-43 amino acid peptides that are derived from the proteolytic
hydrolysis of amyloid-β precursor protein (AβPP) in neurons and other cell types. (8). The
presence of NFTs is accompanied by gliosis, loss of neurons and synapses (9). Aβ and p-tau lead
to chronic inflammatory response and oxidative damage, resulting in progressive neuronal
degeneration (10). It has been shown that there is a decrease in Aβ42 levels in the cerebrospinal
fluid (CSF) and an increase in CSF p-tau levels that can be a biomarker of pathologic changes in
the brain that ultimately lead to AD or increases the risk of developing the disease. These
changes have been associated in patients with MCI who eventually will develop AD later in life
(11).

Clearance of Aβ and importance of Proteasome
There are three pathways that help to clear Aβ from the brain. They are: transport across bloodbrain barrier (BBB), degradation in the brain tissue, and bulk flow of cerebrospinal fluid (CSF).
However, clearance across BBB is considered to be the most efficient for removing Aβ (8). It is
believed that accumulation of Aβ in AD patients is due to inadequate Aβ elimination, with
patients showing less than 30% clearance of Aβ from the brain (1). The level of Aβ in the brain
is determined by its production and clearance. The imbalance occurs between the two processes
that leads to accumulation of Aβ in the brain (8). It is believed that age-related accumulation of
damaged proteins result both from increased damage and lower efficiency of degradative
systems. The proteasome system most often helps in clearing the oxidatively modified proteins
2

and it is the main pathway that removes damaged proteins and it is responsible for maintaining
the proteostasis especially during stress conditions (12).
However, proteasome function declines with age in various cell types and organs, and this has
been shown in various studies. As a result, decline in the activity of proteasome results in
accumulation of oxidized proteins (12). There are significant implications on various
neurodegenerative diseases due to the reduction in the activity of proteasome and other
intracellular proteolytic machineries (12). Ubiquitin-proteasome system, a part of the protein
quality control system (PQC), helps to degrade misfolded or damaged proteins and removes
proteins involved in various cellular processes, such as, signal transduction, regulation of cell
cycle, cell death, and finally regulates gene transcription. This system uses two strategies in
order to maintain protein homeostasis during protein misfolding (12). Misfolded proteins can be
refolded back in order to recover the normal conformation. Molecular chaperons, such as heat
shock proteins (HSPs), play a vital role in protein refolding (12). In other cases, the proteins are
directed towards the ubiquitin-proteasome system for degradation (12).
Structurally, the 26S proteasome holocomplex consists of a 20S catalytic core and a 19S
regulatory cap on either end. The 20S subunit has four stacked rings that form a barrel-shaped
molecule with a central cavity (13). The α-rings are the outer two non-catalytic rings and the two
catalytic inner rings are known as β-rings. There are three proteolytic activities that are confined
to the β-rings, chymotrypsin-like, caspase-like, and trypsin-like. (13).
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Figure 1: 26S proteasome holocomplex

Growing evidences support that impaired proteostasis result in the increase of
unfolded/misfolded proteins and formation of protein aggregates, which plays a vital role in the
pathology of AD (14). In addition, a study demonstrated that Aβ oligomers, but not monomers,
inhibited the activity of the proteasome in 3xTg-AD mice (pathology of AD is studied in this
type of mice) when there are high levels of the oligomers present. Also, it was shown that there
was accumulation of both Aβ and tau proteins when the activity of proteasome was inhibited
(15). As a result, the proteasome is a vital pathway that links Aβ and tau pathology. Hence, it has
been postulated that the function of the proteasome needs to be enhanced, so that the Aβ could be
effectively cleared from the brain (15).

Function of AIRAP/AIRAPL including earlier studies
Arsenite-inducible RNA-associated protein (AIRAP) and AIRAP-like protein (AIRAPL) are
ubiquitin-binding proteins that help to enhance the activity of proteasome in response to stress
(16). It is demonstrated that functional impairment of AIP-1, a homologue of AIRAP and
AIRAPL leads to acceleration in aging and protein aggregation in Caenorhabditis elegans
disease model (16). In another study, AIP-1 was shown to be overexpressed in C. elegans in
4

what appeared to be a protective response against Aβ toxicity that led to reducing the
accumulation of Aβ. Moreover, it was noted that transgenic expression of AIRAPL, but not
AIRAP expression inhibited the toxicity related to Aβ in the worm model (17). It is evident
from this study that AIRAP did not have a protective effect against Aβ toxicity in the worm
model. But, it is not necessary that it won’t be having any neuroprotective effect in mammals.
Hence, we want to use both AIRAP and AIRAPL and study the effects they have related to Aβ
toxicity in the cells.

OVERALL GOAL
The goal of this study is to test whether AIRAP and AIRAPL are protective against Aβ toxicity
in mammalian neuronal cells. In order to test whether AIRAP and AIRAPL are protective, we
will manipulate the expression of the two genes to test the effect of overexpression and
knockdown on Aβ toxicity.

INNOVATION/ IMPACT
Drug targets that enhance the expression of AIRAP/AIRAPL that in turn reduce the toxicity
related to Aβ could be a potential therapeutic drug target used in case of Alzheimer’s patients.
Hence, if AIRAP/AIRAPL offer protection against Aβ toxicity via enhanced proteasomal
function in mammalian system, it would be useful in decelerating the progression of AD.

5

HYPOTHESIS AND SPECIFIC AIMS
The central hypothesis of this study was that AIRAP and AIRAPL genes are protective
against Aβ toxicity. To examine this hypothesis, I proposed the following specific aims:
Specific Aim 1: To determine Aβ toxicity in mammalian neuronal cells. The working
hypothesis of this aim: Aβ increases cell death and lowers the cell viability in the neuronal cells.
Specific Aim 2: To determine whether AIRAP/AIRAPL genes reduce cell death/ improve
cell viability. The working hypothesis of this aim: AIRAP/AIRAPL improve cell viability of
neuronal cells.
Specific Aim 2.1: To investigate the effect of overexpression of AIRAP/AIRAPL on cell
viability. The working hypothesis of this aim: Overexpression of AIRAP/AIRAPL reduces cell
death and increases the viability of cells. Overexpression was achieved by establishing stably
transfected cell lines overexpressing AIRAP or AIRAPL using a cytomegalovirus (CMV)
constitutive promoter.
Specific Aim 2.2: To determine the effect of knock down of AIRAP/AIRAPL on the cell
viability. The working hypothesis of this aim: Knocking down AIRAP/AIRAPL increases the
cell death and there was lower number of viable cells present. Knock down was achieved using
specific dicer-substrate interfering RNA (DsiRNA).
Specific Aim 3: To ascertain the over-expression of AIRAP/AIRAPL in presence of induced
Aβ. The working hypothesis of this aim: AIRAP/AIRAPL were found to be overexpressed in
presence of Aβ in mammalian neuronal cells.
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MATERIALS AND METHODS
Construction of Plasmids
We have constructed various plasmids containing either AIRAP or AIRAPL gene. Plasmids
pWH017, pWH018, and pWH019 possess different variants of the human Amyloid-β precursor
protein (APP) gene. Next, we transfected the plasmids into the HT22 neuronal cells and studied
the effects of the genes when overexpressed/ knocked out in presence of Aβ treatment.
Moreover, we also designed plasmids without AIRAP and AIRAPL genes (pWH020 and
pWH021 respectively) that served as controls. Detailed description of the plasmids is provided
below.
pWH013 (9853 bp): This was constructed using plasmid pWH002 (containing
human CMV promoter and AIRAP gene) and cut with HindIII enzyme (New
England Biolabs, Ipswich, MA, Cat. No. R3104S). The product of 6557 bp was
ligated with the PCR products of AcGFP (template: pAcGFP1-Hyg-N1 and
primers: CL-AcGFP1-F and CL-AcGFP1-R) of 1625 bp and Hygromycin
(template: pAcGFP1-Hyg-N1 and primers: CL-Hygromycin-F and CLHygromycin-R) of 1725 bp. Cloning was performed using NEBuilder Assembly
(HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No. M5520S;
NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat. No.
N2611A). Transformation was done using high efficiency competent 5α E. coli
cells (New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New
England Biolabs, Ipswich, MA, N3041A).
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Figure 2. Plasmid pWH013

pWH014 (10189 bp): Plasmid pWH001 (presence of human CMV promoter and
AIRAPL gene) was cut with HindIII enzyme (New England Biolabs, Ipswich,
MA, Cat. No. R3104S) and the product of 6557 bp was ligated with the PCR
products of AcGFP (1625 bp) and Hygromycin (1725 bp). This was done with
help of NEBuilder Assembly (HiFi DNA Master Mix: New England Biolabs,
Ipswich, MA, Cat. No. M5520S; NEBuilder Positive Control: New England
Biolabs, Ipswich, MA, Cat. No. N2611A). Transformation was carried out using
high efficiency competent 5α E. coli cells (New England Biolabs, Ipswich, MA,
Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat. No.
B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA, N3041A).
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Figure 3. Plasmid pWH014

pWH015 (9782 bp): This was prepared by cutting pWH013 with NotI enzyme
(New England Biolabs, Ipswich, MA, Cat. No. R3189S). The product of 7931 bp
was ligated with the PCR products of DsRed (template: pCL148 and primers: CLDsRed-F and CL-DsRed-R) of 703 bp and AIRAP (template: AIRAP. PolyA +
CMV promoter and primers: CL-NotI-PolyA+CMV-KpnI-F and CL-NotIPolyA+CMV-KpnI-R) of 1201 bp using NEBuilder Assembly (HiFi DNA Master
Mix: New England Biolabs, Ipswich, MA, Cat. No. M5520S; NEBuilder Positive
Control: New England Biolabs, Ipswich, MA, Cat. No. N2611A). Similarly,
transformation was carried out using high efficiency competent 5α E. coli cells
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(New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New
England Biolabs, Ipswich, MA, N3041A).
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Figure 4. Plasmid pWH015

pWH016 (10118 bp): The plasmid was constructed using pWH014 that was cut
by SpeI enzyme (New England Biolabs, Ipswich, MA, Cat. No. R3133S) +
HindIII enzyme (New England Biolabs, Ipswich, MA, Cat. No. R3104S) and
pWH015 was cut with SpeI enzyme (New England Biolabs, Ipswich, MA, Cat.
No. R3133S) + HindIII enzyme (New England Biolabs, Ipswich, MA, Cat. No.
R3104S). The 2597 bp fragment containing the AIRAPL gene from pWH014 was
ligated with the 7521 bp fragment of pWH015 that had DsRed in it. The ligation
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was carried out using DNA Quick Ligase enzyme (New England Biolabs,
Ipswich, MA, Cat. No. M2200S). Furthermore, transformation was performed
using high efficiency competent 5α E. coli cells (New England Biolabs, Ipswich,
MA, Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat.
No. B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA,
N3041A).
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pWH017 (12272 bp): This was prepared by using pWH004-25 (containing
human Amyloid Precursor Protein wild-type variant 3) that was cut with SapI
enzyme (New England Biolabs, Ipswich, MA, Cat. No. R0569S). The product of
6773 bp was ligated with the PCR products of Tet3G (template: pCMV-tet3G and
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primers: CL-TetOn3G-F and CL-TetOn3G-R) of 2118 bp and Puromycin
(template: pLVX-EF1a-IResPuro and primers: CL-Puromycin-F and CLPuromycin-R) of 3431 bp using NEBuilder Assembly (HiFi DNA Master Mix:
New England Biolabs, Ipswich, MA, Cat. No. M5520S; NEBuilder Positive
Control: New England Biolabs, Ipswich, MA, Cat. No. N2611A). Transformation
was performed by using high efficiency competent 5α E. coli cells (New England
Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New England Biolabs,
Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New England Biolabs,
Ipswich, MA, N3041A).
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Figure 6. Plasmid pWH017
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pWH018: The plasmid was prepared by cutting pWH004-M31 (presence of
human Aβ G37L variant 3) with SapI enzyme (New England Biolabs, Ipswich,
MA, Cat. No. R0569S). The product of 6773 bp was ligated with the PCR
products of Tet3G (2118 bp) and Puromycin (3431 bp) with help of NEBuilder
Assembly (HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No.
M5520S; NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat.
No. N2611A). Transformation was carried out using high efficiency competent 5α
E. coli cells (New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC
Medium: New England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control
DNA: New England Biolabs, Ipswich, MA, N3041A).
.pWH019: This plasmid was constructed by cutting pWH004-32 (human
Amyloid Precursor Protein Swedish variant 3) with SapI enzyme (New England
Biolabs, Ipswich, MA, Cat. No. R0569S). Product of 6773 bp was ligated with the
PCR products of Tet3G (2118 bp) and Puromycin (3431 bp) using NEBuilder
Assembly (HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No.
M5520S; NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat.
No. N2611A). For transformation, high efficiency competent 5α E. coli cells
(New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New
England Biolabs, Ipswich, MA, N3041A) were used.
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pWH020 (8163 bp): This was prepared by using pWH013, cut with SacI enzyme
(New England Biolabs, Ipswich, MA, Cat. No. R3156S) to remove the AIRAP
gene. The larger fragment (containing AcGFP) was ligated using DNA Quick
Ligase enzyme (New England Biolabs, Ipswich, MA, Cat. No. M2200S). The
plasmid was used as a negative control. Consequently, transformation was carried
out using high efficiency competent 5α E. coli cells (New England Biolabs,
Ipswich, MA, Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich,
MA, Cat. No. B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich,
MA, N3041A) were used.
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Figure 7. Plasmid pWH020
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pWH021 (8092 bp): Another negative control plasmid that was constructed by
cutting pWH015 using SacI enzyme (New England Biolabs, Ipswich, MA, Cat.
No. R3156S). DsRed gene was present in the larger fragment and the two ends
were ligated using DNA Quick Ligase enzyme (New England Biolabs, Ipswich,
MA, Cat. No. M2200S). Finally, transformation was performed using high
efficiency competent 5α E. coli cells (New England Biolabs, Ipswich, MA, Cat.
No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat. No.
B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA, N3041A).
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Figure 8. Plasmid pWH021
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Plasmid DNA extraction
Transformation gave rise to bacterial colonies, those were picked and grown overnight in
presence of LB media (DifcoTM LB AGAR, MILLER, Becton Dickson and Company, Sparks,
MD, Cat. No. 244520) containing Ampicillin (ThermoFisher Scientific, Waltham, MA, Cat. No.
11593027). 1 ml of 100 mg/ml Ampicillin was added to 1 L of LB media (40 g of LB AGAR
powder was dissolved in Milli-Q water to make up the total volume up to 1 L). Finally, plasmid
DNA was extracted using Monarch Plasmid Miniprep kit (New England Biolabs, Ipswich, MA,
Cat. No. T1010S) following the manufacturer’s instructions.
HT22 cells
The hippocampus is a vital component of the brains of humans and other mammals that plays
essential roles in long-term memory and spatial navigation. The hippocampus is one of the first
regions of the brain to get affected by AD, along with problems related to memory and
disorientation (18). HT22 cells, an immortalized mouse hippocampal cell line, have been widely
used as in vitro model for studying the mechanism of oxidative stress-induced neuronal cell
death (19). Additionally, it is known that glutamate is the main endogenous excitatory
neurotransmitter in the central nervous system. But, high concentrations of this neurotransmitter
are associated with neurotoxicity and might be involved in various neurodegenerative disorders,
such as Alzheimer’s and Parkinson’s disease (20). Mechanisms of glutamate toxicity involve
enhanced production of reactive oxygen species (ROS). In HT22 cells, elevated ROS levels
result in lipid peroxidation, protein oxidation, DNA damage, and ultimately cell death (20).
Thus, HT22 cell line has been mainly used to study glutamate-induced nonreceptor-mediated
neurotoxicity (20).

16

Transfection
HT22 mouse hippocampal cells were seeded 24 hours prior to transfection in a 48-well plate.
Transfection was carried out the following day with help of chemical method. 1.5 μl of
LipofectamineTM 3000 reagent (INVITROGEN, Carlsbad, CA, Cat. No. L3000001) was diluted
with 25 μl of OPTI-MEMTM medium (Gibco, Life Technologies, Gaithersburg, MD, Cat. No.
31985062) in one of the microcentrifuge tubes. 1 μg of plasmid DNA was diluted in 50 μl of
OPTI-MEMTM medium, then 2 μl of P3000TM reagent (INVITROGEN, Carlsbad, CA, Cat. No.
L3000001) was added and mixed thoroughly. This mixture was then added to the diluted
LipofectamineTM 3000 reagent after which it was incubated for 10-15 minutes. Finally, DNAlipid complex was added to the neuronal cells. This was being performed by a lab mate. The
transfected cells were analyzed after 48 hours.

Cell lines
We grew and maintained the following cell lines in order to test our overall goal.
WH1: HT22; pTRE3G_ Zs Green + pCMV_ Tet3G (transactivator)
WH2: HT22; pWH003 (pTRE3G_ Zs Green + Aβ) + pCMV_ Tet3G
WH3: HT22; pWH017
WH4: HT22; pWH018
WH5: HT22; pWH019
WH6: HT22; pWH013
WH7: HT22; pWH014
WH8: HT22; pWH015
17

WH9: HT22; pWH016
WH10: HT22; WH1 + pWH021
WH11: HT22; WH1 + pWH015
WH12: HT22; WH1 + pWH016
WH13: HT22; WH2 + pWH021
WH14: HT22; WH2 + pWH015
WH15: HT22; WH2 + pWH016
WH16: HT22; pWH020
WH17: HT22; pWH021
WH18: HT22; pWH020 + pWH021

Culture of cell lines
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, CORNING, Corning, NY,
Cat. No. 10-013-CV) with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, Cat. No.
F6178), 1% penicillin/streptomycin (P/S, ThermoFisher Scientific, Waltham, MA, Cat. No.
15140122), and 0.1% gentamycin (Lonza, Walkersville, MD, Cat. No. 17-518Z). All cells were
incubated at 370C in 5% CO2 for propagation. Cell lines took time to grow, and this was
dependent on the particular cell line. When the cells reached an appropriate number, the growth
medium was aspirated off. We added 1 ml of trypsin (CORNING, Corning, NY, Cat. No. 25053-C1) to the cells in a T-25 flask and incubated at 370C for three minutes. This helped the
attached cells to come off the bottom of the flask. 1 ml of DMEM was added to the cells already
incubated with trypsin. Next, the cells were centrifuged at 500 x g for five minutes. The
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supernatant was aspirated off the cell pellet and discarded. The cell pellet was resuspended in a
volume of DMEM, vortexed so that the cells mixed uniformly in the growth medium.

Growth rate and Confluence (%) of HT22 and HCN-2
HT22 mouse hippocampal cells (14th passage) and HCN-2 human cortical cells (6th passage)
were grown in 96-well plate. The cells were treated with 20 μl trypsin (CORNING, Corning,
NY, Cat. No. 25-053-C1), and were allowed to come off the bottom of the plate. It was then
resuspended in 20 μl DMEM (CORNING, Corning, NY, Cat. No. 10-013-CV), mixed
thoroughly by vortexing, and the total number was assessed using a hemacytometer (Hausser
Scientific, VWR, Radnor, PA, Cat. No. 23649-061). From the total cell count, growth rate and %
confluence was studied for both cell types. 100% confluence was estimated if the number of cells
reached 40,000 in one of the wells of a 96-well plate. Initially, 2000 cells each of HT22 and
HCN-2 were seeded in the 96-well plate. After every 24 hours for 9 days, the cells were counted
for growth rate and confluence (%).

=

÷
where ‘n’ denotes the number of days.

Cell viability assays
Neurobasal medium (Gibco, Invitrogen, Carlsbad, CA, Cat. No. 21103049) was added to WH1
and WH2 cell lines that were differentiated after 48 hours. In 100 ml Neurobasal medium, 1 ml
N-2 Supplement (100X) and 2 mM L-glutamine was aseptically added. Next, the differentiated
cells were seeded in a 48-well plate. Two repeats each of WH1 subclone (WH1 2 and WH1 3)
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and WH2 subclone (WH2 1 and WH2 2) were considered for this assay. Doxycycline (1:1000
dilution in DMEM) was added eventually and the cells were kept in the CO2 incubator for 72
hours. This step helped to induce the production of green fluorescent protein (GFP) in WH1 and
WH2 cells and amyloid-beta protein (Aβ) in WH2 cells. Cell viability assay was performed
using Annexin V-Cy3 Apoptosis kit (BioVision, Milpitas, CA, Cat. No. K102-25). The DMEM
was aspirated off and the cells were resuspended in 250 µl of 1X Annexin Binding Buffer. 2.5 µl
of Annexin V-Cy3 was added and incubated for 10 minutes in dark. Finally, the cells were
observed under a fluorescent microscope using a rhodamine filter. The apoptotic cells gave faint
red color, while the dead ones were bright red. On the other hand, the live cells did not fluoresce
at all.

Next, cell lines WH8, WH9, and HT22 (control) were differentiated using neurobasal medium.
The cells were eventually seeded (~ 125000) in a 6-well plate. 20 µM Aβ1-42 was added from
1 mM Aβ1-42 stock to the three wells containing WH8, WH9, and HT22. The other three wells of
the plate had only DMEM without Aβ. The cells were kept in the CO2 incubator for 48 hours.
After the incubation period, cell viability was performed using 0.4% Trypan Blue Solution
(Amresco, Solon, OH, Cat. No. K940). The cells were trypsinized and resuspended in 1 ml
DMEM after which they were centrifuged at 500 x g for five minutes. The supernatant was
aspirated off and the cell pellet was dissolved and mixed thoroughly in 180 μl of phosphate
buffer saline (PBS, HyClone, Logan, UT, Cat. No. SH30256.01). Finally, 20 μl of 0.4% Trypan
Blue Solution (1:10 volume of PBS) was added to the cells. The cells were incubated for 10
minutes after which they were counted using a hemacytometer. The dead cells were stained blue
by the stain, while the live cells were clear and translucent.

20

Differentiated HT22 cells were seeded (~ 40000) in a 48-well plate. Following day, the cells
were transfected chemically with AIRAP DsiRNA (Integrated DNA Technologies, IDT,
Coralville, IA, Cat. No. N001159908.1, N133349.12.3, and N133349.12.1) and AIRAPL
DsiRNA (IDT, Coralville, IA, Cat. No. N001159905.1, N026846.12.12, and N001159906.1)
along with negative control (NC-1, IDT, Coralville, IA, Cat. No. 51-01-14-04). 2.1 µl each of
AIRAP DsiRNA, AIRAPL DsiRNA, and NC-1 from 50 µM stocks were added to the cells. After
24 hours, the transfected cells were transferred from 48-well plate to 6-well plate. Finally, 20 µM
Aβ1-42 was added from 1 mM Aβ1-42 stock to three wells containing HT22/AIRAP DsiRNA,
HT22/AIRAPL DsiRNA, and HT22/NC-1. The other three wells containing the same set of cells
did not have Aβ in them. The cells were incubated for 48 hours, after which they were stained
using 0.4% Trypan Blue Solution and the cells were counted using a hemacytometer, following
the same protocol that was used with cells lines WH8 and WH9.

RNA isolation
Doxycycline was added to WH1 (subclones 2 and 3), WH2 (subclones 1 and 2), HT22 cells and
were seeded in a 6-well plate. WH1 and WH2 cells were harvested after 4, 8, 12, and 16-hour
interval and HT22 cells were harvested after 0, 4, 8, 12, and 16-hour interval in 500 μl TRI
Reagent Solution (RNA isolation reagent, Invitrogen, Thermo Fisher Scientific, Carlsbad, CA,
Cat. No. AM9738). 50 μl of 1-Bromo-3-Chloropropane (Sigma-Aldrich, St. Louis, MO, Cat. No.
B9673) was added to the samples in microcentrifuge tubes. The tubes were shaken vigorously
for 30 seconds after which they were incubated for 3 minutes at room temperature. Next, the
samples were centrifuged at 12000 x g for 15 minutes. The supernatant was transferred to
another set of tubes that already had 250 μl of 2-Propanol (Sigma-Aldrich, St. Louis, MO, Cat.
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No. I9516). The tubes were thoroughly vortexed after which the samples were incubated for 10
minutes at room temperature. Eventually, samples were centrifuged at 12000 x g for 10 minutes.
The supernatant was aspirated off and the pellet was washed with 500 μl of 75% ethanol.
Samples were again centrifuged at 7500 x g for 5 minutes. The pellet was let to dry and finally it
was dissolved in 50 μl of RNase free water. The samples were incubated at 550C water bath for
10 minutes before further analysis.

cDNA synthesis and Real-Time PCR
The RNA samples were next used to make copies of complementary DNA (cDNA) using the
manufacturer’s instructions (Takara, Mountain View, CA, Cat. No. RR037A). The cDNA
samples were used to test the expression of AIRAP and AIRAPL using mouse AIRAP
(PrimeTime qPCR Primers, IDT, Coralville, IA, Cat. No. 127013791) and AIRAPL (qPCRAIRAPL-Ms-F, qPCR-AIRAPL-Ms-R, IDT, Coralville, IA, Cat. No. 114282272 and
114282273) primers, besides using the housekeeping primers, PGK1 (qPCR-PGK1-Ms-F,
qPCR-PGK1-Ms-R, IDT, Coralville, IA, Cat. No. 114282325 and 114282324) and RPS18
(qPCR-RPS18-Ms-F, qPCR-RPS18-Ms-R, IDT, Coralville, IA, Cat. No. 114282323 and
114282322). We used SYBR Select Master Mix dye (Applied Biosystems, Life Technologies,
Austin, TX, Cat. No. 4472897) to perform real-time PCR (StepOnePlus, Applied Biosystems,
Waltham, MA, Cat. No. 4376300) and study the expression levels of AIRAP and AIRAPL.
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Statistical Analysis
Two-sample student t-test assuming unequal variances was performed to test if significant results
were obtained in the experiments. Differences between experimental groups were considered
statistically significant if the P-value was ≤ 0.05.
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RESULTS

Characterization of HT22 and HCN-2 cells
To characterize HT22 (14th passage) and HCN-2 (6th passage) cells, the cell number, growth
rate, and confluence (%) were recorded for nine days at 24-hour intervals. As shown in Figure
9A and 9B, starting with 2000 cells at day “0”, both cell types continued to grow until the 9th
day, although the rate of proliferation decreased at day “6” (HT22) and day “7” (HCN-2).
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Figure 9. Characterization of HT22 and HCN-2 cells. Both HT22 (A) and HCN-2 (B) were
seeded at 2,000 cells/well in 96-well plate. All cells were incubated overnight and counted after
every 24 hours, right after they were seeded. Cells were collected by trypsinization, and total
cells were counted using a hemacytometer.

Next, as shown in Figure 10A and 10B, the growth rate of HT22 and HCN-2 cells were
calculated from the total cell number for nine days. It was observed that the growth rate of HT22
was decreased after day “5”. This could be primarily due to the increase in number of cells with
time in the 96-well plate. This showed that the cells started dividing and after a certain point
when they were many as compared to the area of the 96-well plate, they stopped dividing. The
growth rate of HCN-2 was analyzed and found that after day “6”, the cells started to divide
slowly and hence their growth rate was lowered as compared to the days in the beginning.
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Figure 10. Growth rate of HT22 and HCN-2 cells. Growth rate was calculated for nine days
from the total cell count. For HT22 (A), it was similar right from the beginning, but after day
“5”, it decreased till the last day. In case of HCN-2 (B), the growth rate was reduced after day
“6”.

As shown in Figure 11A and 11B, the confluence (%) of HT22 and HCN-2 cells were calculated
from the total cell count. This was done in order to see the effect of confluence on cell growth.
It is estimated that if the total cell count was 40,000 in one of the wells of the 96-well plate, the
confluence would be 100%. Based on that, the confluence was calculated for both HT22 and
HCN-2 cells for nine days. On day “0”, both HT22 and HCN-2 cells had 5% confluence as 2000
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cells were seeded on that day. The confluence reached 65.81% on day “3” and went up to
135.5% on day “4”, for HT22 cells, since the number of cells were 54,200. The confluence was
found to be 397.5% on day “9”, since the total number of cells were 159,000. Similarly, the
confluence of HCN-2 was 100.08% on day “5”, as number of cells were 40,033. On day “9”, the
confluence was found to be 385.12%, the number of cells being at 154,048. The confluence had
a direct effect on the growth rate, for HT22, it went from 235.75% to 276.25% from day “5” to
day “6”. Also, for HCN-2, the confluence was 175.12% on day “6”, and 222.50% on day “7”.
This showed that the confluence did not increase in the same way as on the initial days after
seeding in both cell types. As a result, the growth rate was lowered after day “5” in HT22 and
after day “6” in HCN-2 cells.
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Figure 11. Confluence (%) of HT22 and HCN-2 cells. Confluence was calculated for nine
days based on: 40,000 cells/well = 100% confluence. There was an increase in the confluence of
both HT22 and HCN-2 cells, each day, through nine days. But, the increase in confluence was
lowered after day “5” in HT22 (A), and day “6” in HCN-2 (B), that in turn affected the growth
rate in both cell types.

Toxicity of Aβ on the neuronal cells
WH1 (control) and WH2 cell lines were used for cell viability assay using Annexin V-Cy3
Apoptosis kit. We used doxycycline-inducible system to trigger the production of Aβ.
Doxycycline was added to both cell lines that were differentiated and incubated for 3 days. The
apoptotic cells were stained red by the stain and cell viability (%) was calculated based on the
number of dead cells present.
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Table 1: % dead of differentiated WH1 and WH2 subclones with 72-hour Doxycycline
treatment.
Name of subclones
Total Cells
Dead Cells
% Dead
WH1 2

308

1

0.32

WH1 3

432

2

0.46

WH2 1

229

6

2.62

WH2 2

282

7

2.48

The WH2 cells were sicker (most likely due to the presence of Aβ) than the WH1 cell lines, as
evident under the microscope. Some of them died after the incubation period in presence of
doxycycline, and so, we calculated the number of viable cells present. However, most of the
WH2 cells did not die, but were sicker and had undergone apoptosis as compared to the WH1
subclones, which was evident from the calculated higher % dead after staining. The apoptotic
and dead cells fluoresced red, while the live cells had no fluorescence.

AIRAP/AIRAPL protection against Aβ toxicity
Cell lines WH8, WH9, and HT22 (control) were used to study the protection of AIRAP/AIRAPL
against Aβ. Aβ was added extracellularly and the differentiated cells were stained with Trypan
Blue Solution after 2-day incubation.
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Table 2: % dead cells in differentiated WH8, WH9, and HT22 after adding Aβ
extracellularly and incubating for 2 days. Both WH8 and WH9 (6.40% and 6.57%
respectively) had fewer dead cells compared to HT22 cells (8.04%).
Name of Cell Lines
Total Cells
Dead Cells
% Dead
WH8 (without Aβ)

236

12

5.08

WH8 + Aβ

125

8

6.40

WH9 (without Aβ)

507

16

3.15

WH9 + Aβ

350

23

6.57

HT22 (without Aβ)

1700

148

8.70

HT22 + Aβ

1193

96

8.04

The percentage of dead cells was calculated in the presence and absence of Aβ. % dead in WH8
and WH9 in presence of Aβ was found to be 6.40 and 6.57 respectively. Additionally, % dead in
HT22 cells (control) in presence of Aβ was 8.04. This data is consistent with protection offered
by AIRAP (WH8) and AIRAPL (WH9), since both cell lines had lower numbers of dead cells
than the HT22 cells. However, the number of HT22 cells were way higher than both WH8 and
WH9 during the time of counting. Moreover, HT22 cells without Aβ had higher % dead than
HT22 with Aβ, which was most likely due to experimental variations.. This and the lack of
repeats make this experiment hard to interpret.. Future experiments, should include multiple
repeats of each condition- preferably 4 or more- and a standardized cell number and density. The
inclusion of HT22 expressing an irrelevant protein (e.g. GFP or DsRed) as an additional control
would also be advisable.
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Effect of AIRAP/AIRAPL knockdown on Aβ toxicity
Differentiated HT22 cells were used to knockdown the expression of AIRAP and AIRAPL with
help of specific DsiRNA. Negative control (NC) was used where AIRAP and AIRAPL
expression was not targeted. . Aβ was added extracellularly and the cells were stained with
Trypan Blue Solution after a 2-day incubation.
Table 3: % dead cells when AIRAP and AIRAPL expression have been knocked down in
presence of extracellular Aβ. The cells where AIRAP and AIRAPL expressions were knocked
down had more dead cells (12.92% and 15.71% respectively) compared to the NC, where the
expressions were restored.
Name of Cell Lines
Total Cells
Dead Cells
% Dead
HT22/AIRAPi
(without Aβ)
HT22/AIRAPi + Aβ

1382

142

10.27

1416

183

12.92

HT22/AIRAPLi
(without Aβ)
HT22/AIRAPLi + Aβ

1460

108

7.39

1012

159

15.71

HT22/NC
(without Aβ)
HT22/NC + Aβ

2154

257

11.93

1510

145

9.60

The percentage of dead cells was calculated both in presence and absence of Aβ. Cells where
AIRAP and AIRAPL expression were knocked down and treated with Aβ (HT22/AIRAPi + Aβ
and HT22/AIRAPLi + Aβ), had 12.92% and 15.71% dead cells respectively, whereas HT22/NC
+ Aβ had 9.60% cells that were dead. This is consistent with our hypothesis that knockdown of
AIRAP/AIRAPL increases cell death, thus lowering the number of viable cells. However, there
were higher numbers of dead cells in HT22/NC in absence of Aβ (11.93%) than in presence of
Aβ (9.60%), although there were more number of cells in HT22/NC than in HT22/NC + Aβ,
which could account for higher dead cells at the end of incubation period. It is not possible to
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interpret this data in the absence of experimental repeats. Therefore, additional experiments are
needed before a final conclusion can be made.

Expression of AIRAP and AIRAPL in response to induced Aβ
Real-time PCR was performed on WH1 (subclones 2 and 3) and WH2 (subclones 1 and 2) that
were treated with doxycycline and harvested after 4, 8, 12, 16, 24, and 48-hour interval (T4T48). Both WH1 (denoted by “GFP”) and WH2 (denoted by “Aβ”) were treated in the absence
of doxycycline and harvested right away after seeding (T0). It was observed that expression of
AIRAP (Figure 12A) in WH2 cells was increased at 4 and 8-hour interval when compared to
WH1 cells, although the increase was not statistically significant (P-value ≤ 0.7402). At 12-hour
interval, the expression level was similar in both WH1 and WH2 cells with an increased AIRAP
level in WH1 cells at the 16-hour interval. However, AIRAP expression was not enhanced in
WH2 cells at 16-hour interval. By the end of 24 and 48-hour interval, it was observed that the
expression dropped drastically in both WH1 and WH2 cells. Also, at T0, the expression was
lowered in WH2 cells.
As shown in Figure 12B, there was a steady increase in the expression of AIRAPL in WH2 cells
as compared to WH1 cells at 0, 4, 8, and 12-hour interval, although the change was not
statistically significant (P-value ≤ 0.5048). However, AIRAPL expression was reduced in WH2
cells as compared to WH1 at 16, 24, and 48-hour interval.
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Figure 12: Time-course experiment showing expression of AIRAP (A) and AIRAPL (B) in
WH1 and WH2 cells at 0, 4, 8, 12, 16, 24, and 48-hour interval with doxycycline treatment.
WH2 cells had enhanced AIRAP expression than WH1 at 4 and 8-hour interval while AIRAPL
expression was enhanced at 0 till 12-hour interval in WH2. AIRAP expression was increased in
WH1 cells at the 16-hour interval, while AIRAPL expression was enhanced in WH1 cells at 16,
24, and 48-hour interval. The data was normalized to WH1 T0 for both AIRAP and AIRAPL.
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Furthermore, we wanted to study AIRAP and AIRAPL expressions in absence of Aβ induction
in WH1 (GFP) and WH2 (Aβ) cells to confirm that any changes in AIRAP and AIRAPL
expression levels found after induction were due to the expression of the transgene, rather than
inherent differences between the two cell lines. It was shown that there were no statistically
significant differences in AIRAP and AIRAPL expression between uninduced WH2 and WH1
cells. (Figures 13A and 13B).
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Figure 13: AIRAP (A) and AIRAPL (B) expressions in WH1 and WH2 cells in absence of
doxycycline. WH2 cells had moderate increase in expression of AIRAP and AIRAPL than WH1
cells.
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DISCUSSION

In this study, we hypothesized that AIRAP and AIRAPL could have a protective effect on the
toxicity related to Aβ in mouse hippocampal cells. We used cell lines, WH1 and WH2, to
determine the toxicity of Aβ. We may have found higher percentage of apoptotic and dead cells
in WH2 than in WH1 after inducing the production of Aβ in WH2 cells via doxycycline.
Although, doxycycline helped to induce Aβ intracellularly in WH2, the cells were not
completely abolished after 3-days incubation period. However, most of the cells went into
apoptotic stage, which was evident from the red fluorescence of the cells when stained with
Annexin V. The WH2 cells appeared sicker than WH1. The live or the healthy cells were not
stained at all, this was more frequently seen in WH1 cells, since the cell line did not have Aβ in
them. We also used WH1 and WH2 cells without adding doxycycline in order to prevent the
production of Aβ. It was found that the viability of WH1 and WH2 cells were similar after the
incubation period. This was due to inability of WH2 cells to produce Aβ in absence of
doxycycline, thus the cells were healthier and more viable.

Next, we wanted to study the effect of AIRAP and AIRAPL overexpression on Aβ toxicity. We
used cell lines, WH8 and WH9, where AIRAP and AIRAPL were overexpressed using a CMV
constitutive promoter. After treating the cells with Aβ1-42, it was found that there were fewer
dead cells in WH8 and WH9 compared to the HT22 cells that were treated with Aβ1-42 as well.
This conclusion is consistent with our hypothesis that AIRAP/AIRAPL overexpression could
have a protective effect on the Aβ toxicity. One major drawback related to this particular
conclusion could be the presence of fewer cells in WH8 and WH9 as compared to the HT22 cells
after the incubation period. This might be due to the different rate of growing of HT22 and
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WH8/WH9 cells. Furthermore, it was also found that the cells treated with Aβ1-42 had lesser
number of cells after the incubation period as compared to the cells without Aβ1-42, although,
equal number of cells were seeded at the beginning of the experiment. This could be due to Aβ
inhibiting the normal growth of cells. Moreover, it was found that there were higher number of
dead cells in HT22 without Aβ than in HT22 with Aβ due to experimental variations, although,
Aβ is known to be toxic to the hippocampal cells. Besides, we did not use more repeats of WH8,
WH9, and HT22 with/without Aβ, which would have helped to get a conclusive result.

Additionally, we wanted to study viability of cells after knocking down AIRAP/AIRAPL
expression to confirm that AIRAP/AIRAPL were actually responsible for the protection against
Aβ. We used HT22 cells and knocked down AIRAP and AIRAPL expression with help of
specific DsiRNA. Eventually, the cells were treated with Aβ1-42 and stained using Trypan Blue
Solution. Higher percentage of the number of dead cells appeared to be in cells where the
expression of AIRAP/AIRAPL was knocked out (HT22/AIRAPi + Aβ and HT22/AIRAPLi +
Aβ) as compared to cells having intact expression of both the genes. In other words, presence of
AIRAP and AIRAPL contributed to higher number of viable cells that was shown in HT22/NC +
Aβ. Hence, it was inferred that in absence of AIRAP and AIRAPL, the condition of the cells
worsened and so we got more number of dead cells. However, we should have used more repeats
of the cell lines in order to provide a more detailed explanation of the protection offered by
AIRAP/AIRAPL against Aβ toxicity. Future studies should aim to consider more repeats of each
condition (AIRAP/AIRAPL knockdown, cell lines having intact expression of AIRAP/AIRAPL,
as well as presence/absence of Aβ) to make a final conclusion.
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Finally, we studied the gene expression of AIRAP and AIRAPL in presence of GFP and Aβ that
was induced with help of doxycycline. WH1 and WH2 cells were treated with doxycycline at
different intervals such as 4, 8, 12, 16, 24, and 48-hour. It was found that WH2 cells had higher
levels of both AIRAP and AIRAPL (although not statistically significant) during the initial
stages of induction of Aβ (4 and 8 hour) as compared to WH1. For the 12-hour treatment, both
WH1 and WH2 cells had similar levels of AIRAP, although, AIRAPL expression was enhanced
but not significantly in WH2 than in WH1 at 12-hour induction with doxycycline. But, it was
found that by the 16-hour treatment with doxycycline, levels of AIRAP and AIRAPL decreased
in WH2 than in WH1 cells. This could be due to the reduction of the effect of Aβ production
with increase in the treatment time, thus lowering the gene expression levels. We also studied the
expression levels in absence of doxycycline. It was shown that there were no statistically
significant differences in AIRAP and AIRAPL expression levels in uninduced WH1 and WH2
cells. However, the time-course experiment at T0 showed lower AIRAP expression in WH2 than
in WH1. Hence, more studies are required to get conclusive evidences about the expressions of
AIRAP and AIRAPL in response to Aβ induction.

In the present study, we reported for the first time that AIRAP and AIRAPL could have
protective effect against Aβ toxicity in mouse hippocampal cells. Through our findings and from
other related studies, it is clear that Aβ is toxic to the mouse neuronal cells and the cells undergo
apoptosis and eventually die in presence of Aβ. Cell lines that overexpress AIRAP/AIRAPL
(WH8/WH9), appeared to offer protection against Aβ toxicity, thus helping in ameliorating the
condition of the cells. Since, the experiment did not have more repeats, the findings could not be
precise and definitive. Additionally, knockdown of both AIRAP/AIRAPL deteriorated the
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condition of the cells, thus increasing the number of dead cells. Future studies should aim to
consider more repeats of cell lines to get more conclusive results. Also, it would be interesting to
study the effect of proteasome in the protection offered by AIRAP/AIRAPL against Aβ toxicity
and thus could provide the potential mechanism for protection. Furthermore, we studied
AIRAP/AIRAPL gene expression in cells having induced Aβ. It was noted that levels of
AIRAP/AIRAPL were higher (not significant) at initial course of the experiment in cells having
induced Aβ than in cells not having Aβ (having GFP alone). This finding suggested that
AIRAP/AIRAPL was being produced in response to Aβ, which in turn helped to offer protection
against the toxicity. However, with increase in the treatment time with doxycycline, the levels
started to decline in response to Aβ. Finally, in future, it would be exciting to study the effect of
AIRAP/AIRAPL in response to Aβ, added extracellularly to the HT22 cells.
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